Deartment of INternal Medicine
Malmö, 20502, Sweden
NCT Number: NCT03306381
The aim of the present study is to research whether subjects with irritable bowel syndrome (IBS) display epigenetic/genetic changes or altered microbiota compared to a non-IBS control group. Further, we will investigate if these parameters as well as subjective IBS symptoms are affected by a 4-week long dietary intervention within the IBS patient group.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Malmö, 20502, Sweden
The study will be performed on 140 subjects with verified IBS. Patients will be recruited from the clinic of Gastroenterology or Internal medicine as well as primary health care centers. At the start of the study patients will fill out protocols concerning Rom IV criteria (to validate that IBS criteria are filled) as well as IBS symptom rating scales. They will be examined by a physician/researcher who will complete protocols of clinical data. Blood and fecal samples will be collected. A control group of healthy, non-IBS individuals will go through the same procedure as described above.
Study participants with IBS will thereafter be randomized to receive an alternative diet resembling the FODMAP (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols) diet (n=130), or to continue with their regular diet (control group; n=20). After 4 weeks of dietary intervention, there will be a follow-up where blood and fecal samples are once again collected. At this point in time, participants will also fill in IBS symptom rating scales again.
Samples from baseline and 4 weeks will be used for genetic/epigenetic (including genomic-wide association studies), gut microbiota and inflammatory parameter analyses.
Statistics
To study differences in the above-mentioned parameters between patients and controls as well as before and after dietary intervention, Mann-Whitney U-test and Wilcoxon test will be used, respectively.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Elimination of certain products.
Time frame: measured at baseline
Genetic expression of disaccharide-degradating enzymes will be measured at baseline and related to the response of study participants to dietary intervention.
Time frame: 4 weeks
Changes from baseline in subjective symptoms according to the IBS-SSS.
Time frame: 4 weeks
Changes from baseline in subjective symptoms according to the VAS-IBS.
Time frame: 4 weeks
Changes from baseline in fecal microbiota analysed by 16rs
Time frame: 4 weeks
Changes from baseline in cytokine plasma concentrations will be assessed by ELISA.
Time frame: 4 weeks
Changes from baseline in microRNA expression will be assessed.
Region Skane
Other
The Effect of Dietary Intervention on Symptoms in Relation to Genetical Characteristics, Epigenetics, Gut Microbiota, and Autoantibodies in IBS Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04348760
Colonic Diseases, Colonic Diseases, Functional
Milan, Italy
View Trial DetailsNCT07089420
Colitis, Colitis, Ulcerative
Salem, New Hampshire, United States
View Trial DetailsNCT05995899
Colonic Diseases, Colonic Diseases, Functional
Boston, Massachusetts, United States
View Trial DetailsNCT06297785
Colonic Diseases, Colonic Diseases, Functional
Gothenburg, Sweden
View Trial Details